Vaccines & Disease · Chickenpox

Chickenpox (Varicella): Quick Facts

Published October 12, 2021 · 7 min read
Toddler held by an adult, showing small red spots scattered across the child's back and shoulders
01

What is Chickenpox (Varicella)?

  • Chickenpox (varicella zoster) is caused by the varicella-zoster virus (VZV), a double-stranded DNA virus in the herpesvirus family. Primary infection produces chickenpox that begins with small, itchy raised red spots on the face, chest, back and other parts of the body before becoming blister-like lesions that eventually break open and crust over during healing. Depending upon the individual, the number of chickenpox lesions can vary from a handful to covering large areas of the body. After the initial varicella zoster infection resolves, the virus remains latent in sensory nerve ganglia. Reactivation of latent VZV later in life can cause herpes zoster, commonly known as shingles.12
  • Symptoms of chickenpox typically appear 10 to 21 days after exposure to the virus, and the illness generally lasts about four to seven days. In adults and older children, early symptoms may include fever, fatigue, loss of appetite, headache, runny nose and cough, which can occur one to two days before the rash appears and, during this time, the person can transmit the infection. In many children, the rash is often the first recognizable sign of infection with the varicella zoster virus.34
  • Chickenpox can occur in vaccinated individuals and is referred to as breakthrough varicella. Breakthrough infections may be milder than infections in unvaccinated persons and may involve fewer than 50 skin lesions. The rash may appear more as papules than vesicles, with fever occuring less frequently. Approximately 25 to 30 percent of people who develop varicella after receiving one dose of the vaccine may experience illness that resembles natural chickenpox. A person with breakthrough chickenpox is still contagious and can transmit the virus to others.
  • Before the licensing of the varicella vaccine in 1995, chickenpox was a common childhood infection in the United States. The CDC estimated more than 4 million cases occurred each year, with between 10,5000 and 13,500 hospitalizations and 100 to 150 deaths, and most infections occurred in children younger than 15 years of age5. The highest infection rates were observed among children between one and four years of age, followed by children between five and nine years old. In the pre-vaccine era, only a small percentage of chickenpox cases occurred in adult populations due to naturally acquired immunity that was asymptomatically boosted throughout life by adults coming into contact with children infected with varicella zoster.6 Varicella was removed from the list of nationally reportable diseases in 1981 and was reinstated as a nationally reportable disease in 2003.7
  • Chickenpox-related deaths have been nationally notifiable in the United States since 1999. In 2019, six deaths associated with chickenpox were reported, and in 2020 one chickenpox-related death was reported to the CDC.8
  • Recovery from chickenpox generally results in long lasting immunity, and second cases are uncommon in immunocompetent individuals. Exposure to varicella-zoster virus after a prior infection can boost immunity and may help reduce the risk of developing shingles later in life.9
02

The Chickenpox Vaccine

  • Two varicella-containing vaccines are licensed for use in the United States: Varivax, a single-antigen live attenuated varicella vaccine manufactured by Merck, and ProQuad (MMRV), a combination live attenuated vaccine that protects against measles, mumps, rubella, and varicella. ProQuad is licensed for use in children 12 months through 12 years of age, while Varivax may be used in children, adolescents, and adults.10
  • Varivax is a live attenuated varicella vaccine that contains the Oka/Merck strain of varicella-zoster virus. The strain was originally isolated from a child with naturally occurring varicella and was attenuated through serial passage in cell cultures, including human embryonic lung cells, embryonic guinea pig cells, and human diploid cell cultures such as WI-38 and MRC-5.11
  • Varivax is a lyophilized preparation that contains stabilizers including sucrose, gelatin, monosodium L-glutamate, and phosphate buffers. When reconstituted as directed, each approximately 0.5 mL dose contains a minimum of 1,350 plaque-forming units (PFU) of the Oka/Merck strain of varicella virus. The vaccine also contains hydrolyzed gelatin, sodium chloride, sucrose, sodium phosphate dibasic, potassium phosphate monobasic, and potassium chloride. Residual components from the MRC-5 human diploid cell culture used in manufacturing may be present, including small amounts of cellular DNA and protein, as well as trace quantities of neomycin, EDTA, and fetal bovine serum. Varivax is to be administered promptly after reconstitution and may be given by subcutaneous injection.12
  • ProQuad (MMRV) is a live attenuated combination vaccine that protects against measles, mumps, rubella, and varicella and is licensed for use in children 12 months through 12 years of age. The vaccine contains the components of M-M-R II and the Oka/Merck strain of varicella-zoster virus propagated in MRC-5 human diploid cells. The viruses are grown in buffered cell culture media containing vitamins and amino acids and supplemented with fetal bovine serum and other stabilizers, including sorbitol and hydrolyzed gelatin. ProQuad is supplied as a sterile lyophilized preparation and may be administered by subcutaneous or intramuscular injection.13
  • The CDC recommends that children receive the first dose of varicella vaccine between 12 and 15 months of age and a second dose between 4 and 6 years. The CDC also recommends two doses of varicella vaccine, administered 4 to 8 weeks apart, for older children, adolescents, and adults without evidence of immunity.14
03

Natural Immunity vs. Vaccine Immunity

  • Natural Immunity: Recovery from chickenpox (varicella zoster) generally results in long-lasting immunity. Repeat infections with the varicella zoster virus are uncommon in immunocompetent individuals. After the initial infection resolves, the varicella-zoster virus remains latent in sensory nerve ganglia and may reactivate later in life as herpes zoster (shingles). Re-exposure to varicella-zoster virus after a primary infection can boost antibody levels and immunity without causing symptoms of illness (asymptomatic infection).1516
  • Varicella Vaccine Immunity. Chickenpox vaccine provides temporary vaccine strain immunity that wanes over times. Studies have shown that a single dose of varicella vaccine is less effective than two doses. Breakthrough varicella zoster infections can occur in vaccinated individuals. These breakthrough cases are generally milder than infections in unvaccinated persons, which can involve fewer skin lesions and lower rates of fever. The CDC recommends a two-dose vaccination schedule to reduce the risk of breakthrough disease.1718 Because the symptoms may be less pronounced, breakthrough cases can be more difficult to recognize and diagnose. Studies have documented that outbreaks of chickenpox have occurred in highly vaccinated populations, indicating that transmission can still occur in populations with high vaccination rates.1920 Infected vaccinated individuals remain contagious and can still transmit the virus to close contacts.2122
04

Vaccine Risks & Adverse Events

  • Serious reactions have been reported following receipt of varicella (chickenpox) vaccines, including Varivax and ProQuad. These reactions are described in FDA prescribing information and in peer reviewed medical literature.2324
  • Severe allergic reactions, including anaphylaxis, have been reported after varicella vaccination. Anaphylaxis is a sudden and potentially life-threatening allergic reaction that can cause difficulty breathing, swelling of the throat or face, dizziness, low blood pressure, and shock.2526
  • Neurological reactions including encephalitis and meningitis, which are forms of inflammation affecting the brain or the lining surrounding the brain and spinal cord have also been reported. Symptoms can include severe headache, fever, neck stiffness, vomiting, confusion, seizures, or sensitivity to light. Cases associated with the vaccine strain of varicella virus have been described in medical literature.27
  • Blood related complications have been reported following varicella vaccination. These include thrombocytopenia, a condition in which platelet levels become abnormally low. Platelets help the blood clot. Low platelet levels can cause unusual bruising, small red or purple spots on the skin, nosebleeds, or prolonged bleeding.2829
  • More serious adverse events have also been reported to the Vaccine Adverse Events Reporting System (VAERS) and in medical literature, including autoimmune, neurological, metabolic, and vascular conditions. These and other serious chickenpox vaccine reactions are documented in the medical literature to occur following receipt of chickenpox vaccine.
05

Individual Susceptibility

The Institute of Medicine, National Academy of Sciences, has acknowledged in published reports that:

  • Individuals vary in susceptibility to vaccine reactions due to due to differences in biological, genetic, epigenetic and environmental factors.
  • Doctors and other medical workers administering vaccines often do not know how to predict who will be harmed before vaccination due to gaps in scientific knowledge about who is genetically or otherwise biologically at high risk for suffering harm.
  • A previous vaccine reaction can raise the risks for a reaction after another dose of vaccine.
  • It is very important to consider your health or your child’s health and review your own and your family’s health history for the presence of autoimmune, allergic, neurological and metabolic disorders when making a decision about the timing of vaccination or whether or not to vaccinate.
06

Your Right to Informed Consent

Nobody can guarantee in advance that your child will not be injured by a vaccine or an infectious disease. NVIC supports your legal right to have full information about the risks of a disease and the risks of a vaccine and the freedom to exercise voluntary, informed consent to vaccination without being coerced or sanctioned for the decision made.

NVIC supports the ending of vaccine mandates in every state.

Key Takeaways

  1. Certain groups are at increased risk of complications from chickenpox, including pregnant women, newborns whose mothers develop varicella around the time of delivery, premature infants, and individuals with weakened immune systems.30
  2. Complications following varicella (chickenpox) vaccination have been reported and can include rash, fever, seizures, pneumonia, and infection of the brain or spinal cord coverings in rare cases.31
  3. The US government has awarded compensation to children and adults injured by the chicken pox vaccine.
  4. You have the right to know and should have the freedom to choose whether or not to accept a vaccine risk for your child without being sanctioned for the choice you make.
Bottom Line
Vaccination is not a one-size-fits-all medical intervention. Before you take a risk, find out what it is.

Search for Vaccine Reactions

NVIC hosts MedAlerts, a powerful and user-friendly search engine of the federal Vaccine Adverse Events Reporting System (VAERS). MedAlerts makes it easy to search for vaccine reaction reports to VAERS, including immediate symptoms and long term adverse health outcomes, dates and places the vaccines were administered, ER visits, hospitalizations and more.

IMPORTANT NOTE: NVIC encourages you to become fully informed about Chickenpox (Varicella) and the Chickenpox (Varicella) vaccines, including reviewing the References at the end of this page and reading all sections in the Table of Contents. You will find many useful links and resources with more detailed information, such as the manufacturer product information inserts, that help you make a decision about vaccination. You are also encouraged to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information provided by NVIC is for educational purposes only and is not intended as medical advice.

References
  1. 1Clinical Overview of Chickenpox (Varicella). CDC. Jul. 15, 2024.
  2. 2How to Identify Chickenpox Symptoms and Signs. verywellhealth. Feb. 24, 2026.
  3. 3Clinical Overview of Chickenpox (Varicella). CDC. Jul. 15, 2024.
  4. 4Clinical Overview of Chickenpox (Varicella). CDC. Jul. 15, 2024.
  5. 5Ibid.
  6. 6Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20(19-20): 2500-2507.
  7. 7Pink Book. Varicella. CDC. May 9, 2024.
  8. 8Chickenpox Reporting and Surveillance. CDC. Jul. 31, 2024.
  9. 9Pink Book. Varicella. CDC. May 9, 2024.
  10. 10Varicella (Chickenpox) Vaccination: Information for Health Care Providers. CDC. Apr. 28, 2021.
  11. 11Varivax. FDA.
  12. 12Varivax. FDA.
  13. 13ProQuad. FDA.
  14. 14Varicella (Chickenpox) Vaccination: Information for Health Care Providers. CDC. Apr. 28, 2021.
  15. 15Pink Book. Varicella. CDC. May 9, 2024.
  16. 16Clinical Overview of Chickenpox (Varicella). CDC. Jul. 15, 2024.
  17. 17Clinical Overview of Chickenpox (Varicella). CDC. Jul. 15, 2024.
  18. 18Pink Book. Varicella. CDC. May 9, 2024.
  19. 19Clinical Overview of Chickenpox (Varicella). CDC. Jul. 15, 2024.
  20. 20Pink Book. Varicella. CDC. May 9, 2024.
  21. 21Chapter 17: Varicella. CDC. Nov. 21, 2024.
  22. 22Clinical Manifestations of Varicella: Disease Is Largely Forgotten, but It’s Not Gone. J Infect Dis. Oct. 21, 2022.
  23. 23Varivax. FDA.
  24. 24ProQuad. FDA.
  25. 25Varivax. FDA.
  26. 26ProQuad. FDA.
  27. 27Vaccine Oka Varicella Meningitis in Two Adolescents. Pediatrics. Dec. 2, 2019.
  28. 28Varivax. FDA.
  29. 29ProQuad. FDA.
  30. 30Acute varicella-zoster. BMJ Best Practice.
  31. 31Varicella Vaccine VIS. CDC. Jan. 31, 2025.
Select disease / vaccine

What is Chickenpox (Varicella)?

  • Chickenpox (varicella zoster) is caused by the varicella-zoster virus (VZV), a double-stranded DNA virus in the herpesvirus family. Primary infection produces chickenpox that begins with small, itchy raised red spots on the face, chest, back and other parts of the body before becoming blister-like lesions that eventually break open and crust over during healing. Depending upon the individual, the number of chickenpox lesions can vary from a handful to covering large areas of the body. After the initial varicella zoster infection resolves, the virus remains latent in sensory nerve ganglia. Reactivation of latent VZV later in life can cause herpes zoster, commonly known as shingles.1  2
  • Symptoms of chickenpox typically appear 10 to 21 days after exposure to the virus, and the illness generally lasts about four to seven days. In adults and older children, early symptoms may include fever, fatigue, loss of appetite, headache, runny nose and cough, which can occur one to two days before the rash appears and, during this time, the person can transmit the infection. In many children, the rash is often the first recognizable sign of infection with the varicella zoster virus.3 4
  • Chickenpox can occur in vaccinated individuals and is referred to as breakthrough varicella. Breakthrough infections may be milder than infections in unvaccinated persons and may involve fewer than 50 skin lesions. The rash may appear more as papules than vesicles, with fever occuring less frequently. Approximately 25 to 30 percent of people who develop varicella after receiving one dose of the vaccine may experience illness that resembles natural chickenpox. A person with breakthrough chickenpox is still contagious and can transmit the virus to others.
  • Before the licensing of the varicella vaccine in 1995, chickenpox was a common childhood infection in the United States. The CDC estimated more than 4 million cases occurred each year, with between 10,5000 and 13,500 hospitalizations and 100 to 150 deaths, and most infections occurred in children younger than 15 years of age 5. The highest infection rates were observed among children between one and four years of age, followed by children between five and nine years old. In the pre-vaccine era, only a small percentage of chickenpox cases occurred in adult populations due to naturally acquired immunity that was asymptomatically boosted throughout life by adults coming into contact with children infected with varicella zoster. 6 Varicella was removed from the list of nationally reportable diseases in 1981 and was reinstated as a nationally reportable disease in 2003.7
  • Chickenpox-related deaths have been nationally notifiable in the United States since 1999. In 2019, six deaths associated with chickenpox were reported, and in 2020 one chickenpox-related death was reported to the CDC.8
  • Recovery from chickenpox generally results in long lasting immunity, and second cases are uncommon in immunocompetent individuals. Exposure to varicella-zoster virus after a prior infection can boost immunity and may help reduce the risk of developing shingles later in life.9

The Chickenpox Vaccine

  • Two varicella-containing vaccines are licensed for use in the United States: Varivax, a single-antigen live attenuated varicella vaccine manufactured by Merck, and ProQuad (MMRV), a combination live attenuated vaccine that protects against measles, mumps, rubella, and varicella. ProQuad is licensed for use in children 12 months through 12 years of age, while Varivax may be used in children, adolescents, and adults.10
  • Varivax is a live attenuated varicella vaccine that contains the Oka/Merck strain of varicella-zoster virus. The strain was originally isolated from a child with naturally occurring varicella and was attenuated through serial passage in cell cultures, including human embryonic lung cells, embryonic guinea pig cells, and human diploid cell cultures such as WI-38 and MRC-5.11
  • Varivax is a lyophilized preparation that contains stabilizers including sucrose, gelatin, monosodium L-glutamate, and phosphate buffers. When reconstituted as directed, each approximately 0.5 mL dose contains a minimum of 1,350 plaque-forming units (PFU) of the Oka/Merck strain of varicella virus. The vaccine also contains hydrolyzed gelatin, sodium chloride, sucrose, sodium phosphate dibasic, potassium phosphate monobasic, and potassium chloride. Residual components from the MRC-5 human diploid cell culture used in manufacturing may be present, including small amounts of cellular DNA and protein, as well as trace quantities of neomycin, EDTA, and fetal bovine serum. Varivax is to be administered promptly after reconstitution and may be given by subcutaneous injection.12
  • ProQuad (MMRV) is a live attenuated combination vaccine that protects against measles, mumps, rubella, and varicella and is licensed for use in children 12 months through 12 years of age. The vaccine contains the components of M-M-R II and the Oka/Merck strain of varicella-zoster virus propagated in MRC-5 human diploid cells. The viruses are grown in buffered cell culture media containing vitamins and amino acids and supplemented with fetal bovine serum and other stabilizers, including sorbitol and hydrolyzed gelatin. ProQuad is supplied as a sterile lyophilized preparation and may be administered by subcutaneous or intramuscular injection.13
  • The CDC recommends that children receive the first dose of varicella vaccine between 12 and 15 months of age and a second dose between 4 and 6 years. The CDC also recommends two doses of varicella vaccine, administered 4 to 8 weeks apart, for older children, adolescents, and adults without evidence of immunity.14

Natural Immunity vs. Vaccine Immunity

  • Natural Immunity: Recovery from chickenpox (varicella zoster) generally results in long-lasting immunity. Repeat infections with the varicella zoster virus are uncommon in immunocompetent individuals. After the initial infection resolves, the varicella-zoster virus remains latent in sensory nerve ganglia and may reactivate later in life as herpes zoster (shingles). Re-exposure to varicella-zoster virus after a primary infection can boost antibody levels and immunity without causing symptoms of illness (asymptomatic infection).15  16
  • Varicella Vaccine Immunity. Chickenpox vaccine provides temporary vaccine strain immunity that wanes over times. Studies have shown that a single dose of varicella vaccine is less effective than two doses. Breakthrough varicella zoster infections can occur in vaccinated individuals. These breakthrough cases are generally milder than infections in unvaccinated persons, which can involve fewer skin lesions and lower rates of fever. The CDC recommends a two-dose vaccination schedule to reduce the risk of breakthrough disease.17  18 Because the symptoms may be less pronounced, breakthrough cases can be more difficult to recognize and diagnose. Studies have documented that outbreaks of chickenpox have occurred in highly vaccinated populations, indicating that transmission can still occur in populations with high vaccination rates. 19  20 Infected vaccinated individuals remain contagious and can still transmit the virus to close contacts.21  22

Vaccine Risks & Adverse Events

  • Serious reactions have been reported following receipt of varicella (chickenpox) vaccines, including Varivax and ProQuad. These reactions are described in FDA prescribing information and in peer reviewed medical literature.23.  24
  • Severe allergic reactions, including anaphylaxis, have been reported after varicella vaccination. Anaphylaxis is a sudden and potentially life-threatening allergic reaction that can cause difficulty breathing, swelling of the throat or face, dizziness, low blood pressure, and shock.25 26
  • Neurological reactions including encephalitis and meningitis, which are forms of inflammation affecting the brain or the lining surrounding the brain and spinal cord have also been reported. Symptoms can include severe headache, fever, neck stiffness, vomiting, confusion, seizures, or sensitivity to light. Cases associated with the vaccine strain of varicella virus have been described in medical literature.27
  • Blood related complications have been reported following varicella vaccination. These include thrombocytopenia, a condition in which platelet levels become abnormally low. Platelets help the blood clot. Low platelet levels can cause unusual bruising, small red or purple spots on the skin, nosebleeds, or prolonged bleeding.28  29
  • More serious adverse events have also been reported to the Vaccine Adverse Events Reporting System (VAERS) and in medical literature, including autoimmune, neurological, metabolic, and vascular conditions. These and other serious chickenpox vaccine reactions are documented in the medical literature to occur following receipt of chickenpox vaccine.

Individual Susceptibility

  • The Institute of Medicine, National Academy of Sciences, has acknowledged in published reports that:
  • Individuals vary in susceptibility to vaccine reactions due to due to differences in biological, genetic, epigenetic and environmental factors.
  • Doctors and other medical workers administering vaccines often do not know how to predict who will be harmed before vaccination due to gaps in scientific knowledge about who is genetically or otherwise biologically at high risk for suffering harm.
  • A previous vaccine reaction can raise the risks for a reaction after another dose of vaccine.
  • It is very important to consider your health or your child’s health and review your own and your family’s health history for the presence of autoimmune, allergic, neurological and metabolic disorders when making a decision about the timing of vaccination or whether or not to vaccinate.

Your Right to Informed Consent

Nobody can guarantee in advance that your child will not be injured by a vaccine or an infectious disease. NVIC supports your legal right to have full information about the risks of a disease and the risks of a vaccine and the freedom to exercise voluntary, informed consent to vaccination without being coerced or sanctioned for the decision made. NVIC supports the ending of vaccine mandates in every state.

Key Takeaways

Certain groups are at increased risk of complications from chickenpox, including pregnant women, newborns whose mothers develop varicella around the time of delivery, premature infants, and individuals with weakened immune systems.  30 Complications following varicella (chickenpox) vaccination have been reported and can include rash, fever, seizures, pneumonia, and infection of the brain or spinal cord coverings in rare cases.  31 The US government has awarded compensation to children and adults injured by the chicken pox vaccine. You have the right to know and should have the freedom to choose whether or not to accept a vaccine risk for your child without being sanctioned for the choice you make.

Bottom Line

Vaccination is not a one-size-fits-all medical intervention. Before you take a risk, find out what it is.

Search for Vaccine Reactions

NVIC hosts MedAlerts, a powerful and user-friendly search engine of the federal Vaccine Adverse Events Reporting System (VAERS). MedAlerts makes it easy to search for vaccine reaction reports to VAERS, including immediate symptoms and long term adverse health outcomes, dates and places the vaccines were administered, ER visits, hospitalizations and more.

IMPORTANT NOTE: NVIC encourages you to become fully informed about Chickenpox (Varicella) and the Chickenpox (Varicella) vaccines, including reviewing the References at the end of this page and reading all sections in the Table of Contents. You will find many useful links and resources with more detailed information, such as the manufacturer product information inserts, that help you make a decision about vaccination. You are also encouraged to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information provided by NVIC is for educational purposes only and is not intended as medical advice.